JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
出版年份 2018 全文链接
标题
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-11-23
DOI
10.1038/s41375-018-0295-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
- (2017) Jean-Christophe Ianotto et al. HAEMATOLOGICA
- Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes
- (2017) Lasse Kjaer et al. LEUKEMIA & LYMPHOMA
- Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
- (2017) Jean-Christophe Ianotto et al. HAEMATOLOGICA
- Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses
- (2017) Andrea Majoros et al. Frontiers in Immunology
- Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms
- (2016) M. Araki et al. BLOOD
- Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
- (2016) William Vainchenker et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Response to interferons and antibacterial innate immunity in the absence of tyrosine‐phosphorylated STAT1
- (2016) Andrea Majoros et al. EMBO REPORTS
- Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
- (2016) Lijuan Han et al. Journal of Hematology & Oncology
- Thrombopoietin receptor is required for the oncogenic function of CALR mutants
- (2016) H Nivarthi et al. LEUKEMIA
- Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
- (2016) S Koschmieder et al. LEUKEMIA
- Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
- (2016) Lasse Kjær et al. PLoS One
- Long-acting interferon for myeloproliferative neoplasms - an update
- (2016) Sachin Gopalkrishna Pai et al. Expert Review of Hematology
- Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
- (2016) S. Elf et al. Cancer Discovery
- STAT2 Is a Pervasive Cytokine Regulator due to Its Inhibition of STAT1 in Multiple Signaling Pathways
- (2016) Johnathan Ho et al. PLOS BIOLOGY
- Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
- (2015) Nicole C.C. Them et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical and molecular response to interferon- therapy in essential thrombocythemia patients with CALR mutations
- (2015) E. Verger et al. BLOOD
- Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
- (2015) I. Chachoua et al. BLOOD
- Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
- (2015) C. Marty et al. BLOOD
- Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone
- (2015) J-J Kiladjian et al. LEUKEMIA
- MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
- (2015) Hans Carl Hasselbalch et al. MEDIATORS OF INFLAMMATION
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms
- (2015) Honghe Wan et al. ACS Medicinal Chemistry Letters
- Presence of calreticulin mutations in JAK2-negative polycythemia vera
- (2014) J. Broseus et al. BLOOD
- Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
- (2014) Bruno Cassinat et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy
- (2014) Helen L. Wright et al. RHEUMATOLOGY
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon -2a
- (2013) A. Quintas-Cardama et al. BLOOD
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods
- (2013) Leif Väremo et al. NUCLEIC ACIDS RESEARCH
- A Fusion Cytokine Coupling GMCSF to IL9 Induces Heterologous Receptor Clustering and STAT1 Hyperactivation through JAK2 Promiscuity
- (2013) Pingxin Li et al. PLoS One
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
- (2012) Rita Andraos et al. Cancer Discovery
- Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease
- (2011) C. Elling et al. BLOOD
- Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFN via accelerating the degradation of its receptor
- (2011) S. Bhattacharya et al. BLOOD
- Suppressor of Cytokine Signaling (SOCS) 1 Inhibits Type I Interferon (IFN) Signaling via the Interferon α Receptor (IFNAR1)-associated Tyrosine Kinase Tyk2
- (2011) Rebecca A. R. Piganis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- STAT3 Negatively Regulates Type I IFN-Mediated Antiviral Response
- (2011) W.-B. Wang et al. JOURNAL OF IMMUNOLOGY
- Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2
- (2011) A V Purandare et al. LEUKEMIA
- Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling
- (2010) Edwin Chen et al. CANCER CELL
- Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors
- (2010) Anuradha Pradhan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started